Gail Edwards
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gail Edwards has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Biswadev Mitra
Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia
2 shared publicationsEleanor Van Dyk
Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia
2 shared publicationsGary Yip
Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia
2 shared publications- Biswadev Mitra
School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia
1 shared publication Cristina Roman
Pharmacy Department, The Alfred Hospital, Melbourne, Australia
1 shared publicationErica Y Tong
Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia
1 shared publication
Latest Publications
- 31 January 2024
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 54 (2) , 145-150
The medical emergency team pharmacist: describing an overnight service
- 31 January 2024
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 54 (2) , 145-150
The medical emergency team pharmacist: describing an overnight service
- 23 June 2023
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 30 (4) , 636-641
Implementation of Partnered Pharmacist Medication Charting in haematology and oncology inpatients
Aim: Partnered Pharmacist Medication Charting (PPMC) in patients admitted under general medical units has been shown to reduce medication errors. The aim of this study is to evaluate the impact of the PPMC model on medication errors in patients admitted under cancer units in Victorian hospitals. Methods: A prospective cohort study comparing cohorts before and after the introduction of PPMC was conducted. This included a 2-month pre-intervention phase and 3-month intervention phase. PPMC was implemented during the intervention phase as new model of care that enabled credentialed pharmacists to chart all admission medications, including pre-admission or new medications and cancer therapies, in collaboration with the admitting medical officer. The proportion of medication charts with at least one error was the primary outcome measure. Results: Seven health services across Victoria were included in the study. The majority of health services were using paper-based prescribing systems for oncology. Of the 547 patients who received standard medical medication charting, 331 (60.5%) had at least one medication error identified compared to 18 out of 416 patients (4.3%) using the PPMC model (p < 0.001). The median (interquartile range) inpatient length of stay was 5 (2.9–10.6) days in pre-intervention and 4.9 (2.9–11) days in intervention (p = 0.88). In the intervention arm, 42 patients had cancer therapy charted by a pharmacist with no errors. Conclusions: PPMC was successfully scaled into cancer units as a collaborative medication safety strategy. The model was associated with significantly lower rates of medication errors, including cancer therapies. PPMC should be adopted more widely in cancer units in Australia.
- 23 June 2023
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 30 (4) , 636-641
Implementation of Partnered Pharmacist Medication Charting in haematology and oncology inpatients
Aim: Partnered Pharmacist Medication Charting (PPMC) in patients admitted under general medical units has been shown to reduce medication errors. The aim of this study is to evaluate the impact of the PPMC model on medication errors in patients admitted under cancer units in Victorian hospitals. Methods: A prospective cohort study comparing cohorts before and after the introduction of PPMC was conducted. This included a 2-month pre-intervention phase and 3-month intervention phase. PPMC was implemented during the intervention phase as new model of care that enabled credentialed pharmacists to chart all admission medications, including pre-admission or new medications and cancer therapies, in collaboration with the admitting medical officer. The proportion of medication charts with at least one error was the primary outcome measure. Results: Seven health services across Victoria were included in the study. The majority of health services were using paper-based prescribing systems for oncology. Of the 547 patients who received standard medical medication charting, 331 (60.5%) had at least one medication error identified compared to 18 out of 416 patients (4.3%) using the PPMC model (p < 0.001). The median (interquartile range) inpatient length of stay was 5 (2.9–10.6) days in pre-intervention and 4.9 (2.9–11) days in intervention (p = 0.88). In the intervention arm, 42 patients had cancer therapy charted by a pharmacist with no errors. Conclusions: PPMC was successfully scaled into cancer units as a collaborative medication safety strategy. The model was associated with significantly lower rates of medication errors, including cancer therapies. PPMC should be adopted more widely in cancer units in Australia.
- 8 July 2022
- Published by Wiley in Australian Journal of Rural Health
- Vol. 30 (5) , 593-600
Partnered pharmacist medication charting (PPMC) in regional and rural general medical patients
Objective: Errors in hospital medication charts are commonly encountered and have been associated with morbidity and mortality. This study evaluates the impact of the Partnered Pharmacist Medication Charting (PPMC) model on medication errors in general medical patients admitted to rural and regional hospitals.Design/Method: A prospective cohort study, comparing before and after the introduction of PPMC was conducted in 13 rural and regional health services. This included a 1‐month pre‐intervention phase and 3‐month intervention phase. In the intervention phase, PPMC was implemented as a new model of care in general medical units.Setting: Victoria, Australia.Participants: Patients admitted to General Medical Units.Outcome Measure: The proportion of medication charts with at least one error was the primary outcome measure. Secondary outcome measures included inpatient length of stay (LOS), risk stratification of medication errors, Medical Emergency Team (MET) calls, transfers to ICU and hospital readmission.Results: Of the 669 patients who received standard medical charting during the pre‐intervention period, 446 (66.7%) had at least one medication error identified compared to 64 patients (9.5%) using PPMC model (p < 0.001). There were 1361 medication charting errors identified during pre‐intervention and 80 in the post‐intervention. The median (interquartile range) inpatient length of stay was 4.8 (2.7–10.8) in the pre‐intervention and 3.7 days (2.0–7.0) among patients that received PPMC (p < 0.001).Conclusion: The PPMC model was successfully scaled across rural and regional Victoria as a medication safety strategy. The model was associated with significantly lower rates of medication errors, lower severity of errors and shorter inpatient length of stay.
- 8 July 2022
- Published by Wiley in Australian Journal of Rural Health
- Vol. 30 (5) , 593-600
Partnered pharmacist medication charting (PPMC) in regional and rural general medical patients
Objective: Errors in hospital medication charts are commonly encountered and have been associated with morbidity and mortality. This study evaluates the impact of the Partnered Pharmacist Medication Charting (PPMC) model on medication errors in general medical patients admitted to rural and regional hospitals.Design/Method: A prospective cohort study, comparing before and after the introduction of PPMC was conducted in 13 rural and regional health services. This included a 1‐month pre‐intervention phase and 3‐month intervention phase. In the intervention phase, PPMC was implemented as a new model of care in general medical units.Setting: Victoria, Australia.Participants: Patients admitted to General Medical Units.Outcome Measure: The proportion of medication charts with at least one error was the primary outcome measure. Secondary outcome measures included inpatient length of stay (LOS), risk stratification of medication errors, Medical Emergency Team (MET) calls, transfers to ICU and hospital readmission.Results: Of the 669 patients who received standard medical charting during the pre‐intervention period, 446 (66.7%) had at least one medication error identified compared to 64 patients (9.5%) using PPMC model (p < 0.001). There were 1361 medication charting errors identified during pre‐intervention and 80 in the post‐intervention. The median (interquartile range) inpatient length of stay was 4.8 (2.7–10.8) in the pre‐intervention and 3.7 days (2.0–7.0) among patients that received PPMC (p < 0.001).Conclusion: The PPMC model was successfully scaled across rural and regional Victoria as a medication safety strategy. The model was associated with significantly lower rates of medication errors, lower severity of errors and shorter inpatient length of stay.
- Open Access
- 1 February 2018
- Published by Elsevier in Trauma & Case Reports
- Vol. 13, 46-49
Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
- 1 February 2018
- Published by Elsevier in Trauma & Case Reports
- Vol. 13, 46-49
Open AccessUse of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma